ZYME

27.73

2.78% 0.75

Handel nachbörslich: 27.90 0.17 +0.61%

Zymeworks Inc. (ZYME)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$26.98

Offen:

$27.11

24-Stunden-Volumen:

789.87K

Relative Volume:

1.16

Marktkapitalisierung:

$2.06B

Einnahmen:

$105.97M

Nettoeinkommen (Verlust:

$-81.13M

KGV:

-25.70

EPS:

-1.0791

Netto-Cashflow:

$-35.43M

1W Leistung:

+3.82%

1M Leistung:

+21.20%

6M Leistung:

+48.93%

1J Leistung:

+153.47%

1-Tages-Spanne:

$26.91

$27.92

1-Wochen-Bereich:

$25.83

$27.92

52-Wochen-Spanne:

$10.69

$28.49

Zymeworks Inc. Stock (ZYME) Company Profile

Firmenname

Zymeworks Inc.

Sektor

Healthcare (1112)

Branche

Biotechnology (621)

Telefon

604-678-1388

Adresse

1385 West 8th Avenue, Suite 540, Vancouver, BC

Mitarbeiter

170

Twitter

@ZymeworksInc

Nächster Verdiensttermin

2026-03-02

Neueste SEC-Einreichungen

ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ZYME Zymeworks Inc.	27.73	2.00B	105.97M	-81.13M	-35.43M	-1.0791
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-12	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-12-03	Eingeleitet	Citizens JMP	Mkt Outperform
2025-10-24	Fortgesetzt	Wells Fargo	Equal Weight
2025-10-14	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-10-10	Eingeleitet	B. Riley Securities	Buy
2025-05-20	Eingeleitet	TD Cowen	Buy
2024-12-16	Hochstufung	JP Morgan	Neutral → Overweight
2024-11-07	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-11-01	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-03-21	Fortgesetzt	Wells Fargo	Overweight
2023-01-04	Bestätigt	H.C. Wainwright	Neutral
2022-12-20	Hochstufung	Jefferies	Hold → Buy
2022-11-01	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-10-21	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-10-04	Fortgesetzt	Wells Fargo	Overweight
2022-05-05	Hochstufung	Guggenheim	Neutral → Buy
2022-03-15	Eingeleitet	Evercore ISI	Outperform
2021-12-10	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-11-17	Fortgesetzt	Guggenheim	Neutral
2021-10-07	Eingeleitet	Jefferies	Hold
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-02-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-02-08	Fortgesetzt	H.C. Wainwright	Buy
2021-01-25	Herabstufung	Citigroup	Buy → Neutral
2020-09-29	Fortgesetzt	JP Morgan	Neutral
2020-08-06	Eingeleitet	SVB Leerink	Outperform
2020-01-10	Eingeleitet	Wolfe Research	Outperform
2019-12-09	Eingeleitet	JP Morgan	Neutral
2019-11-25	Eingeleitet	H.C. Wainwright	Buy
2019-11-20	Eingeleitet	Guggenheim	Buy
2019-09-30	Hochstufung	Raymond James	Outperform → Strong Buy
2019-08-30	Eingeleitet	Stifel	Buy
2019-07-18	Eingeleitet	Deutsche Bank	Buy
2018-05-11	Hochstufung	Barclays	Underweight → Equal Weight
2018-03-19	Eingeleitet	Raymond James	Outperform

Alle ansehen

Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten

03:57 AM

Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline strategy is suddenly worth a closer l - AD HOC NEWS

03:57 AM

05:03 AM

Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN

05:03 AM

04:56 AM

Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - MSN

04:56 AM

Apr 14, 2026

How Investors Are Reacting To Zymeworks (ZYME) Elevating EcoR1 Veterans To Key Executive Roles - simplywall.st

Apr 14, 2026

Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline is suddenly worth a closer look - AD HOC NEWS

Apr 14, 2026

Zymeworks (ZYME) executive reports significant option and RSU awards - Stock Titan

Apr 10, 2026

Zymeworks (ZYME) EVP holds 167,000 options and 111,111 RSUs - Stock Titan

Apr 10, 2026

Apr 09, 2026

Zymeworks names Schayowitz as R&D head, Platshon as CBO By Investing.com - Investing.com Australia

Apr 09, 2026

Investment Recap: Should I average down on Zymeworks Inc stock2026 Sector Moves & Verified Momentum Watchlists - baoquankhu1.vn

Apr 09, 2026

Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Apr 09, 2026

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - wahanariau.com

Apr 09, 2026

Zymeworks Bolsters Executive Team to Drive Next Phase of Growth - TipRanks

Apr 09, 2026

Zymeworks names Schayowitz as R&D head, Platshon as CBO - Investing.com

Apr 09, 2026

Buybacks Report: Will Zymeworks Inc benefit from geopolitical trends2026 Intraday Action & Weekly Sector Rotation Insights - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Why Zymeworks (ZYME) Is Up 6.7% After FDA Fast Track Win And CFO Appointment - Sahm

Apr 08, 2026

Apr 07, 2026

Zymeworks (NASDAQ: ZYME) grants CFO large option and RSU awards - Stock Titan

Apr 07, 2026

Zymeworks (NASDAQ: ZYME) CFO reports zero beneficial share ownership - Stock Titan

Apr 07, 2026

Short Squeeze: Will Zymeworks Inc benefit from rising consumer demand2026 Macro Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME - MarketBeat

Apr 06, 2026

A Look At Zymeworks (ZYME) Valuation After Fast Track Win And New CFO Appointment - Sahm

Apr 06, 2026

Apr 04, 2026

ZYME PE Ratio & Valuation, Is ZYME Overvalued - Intellectia AI

Apr 04, 2026

ZYME Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 03, 2026

Zymeworks Inc. R (ZA8.DU) Q1 FY2025 earnings call transcript - Yahoo Finance

Apr 03, 2026

Apr 02, 2026